Despite these findings, little is understood about how FAT10 is involved in fibrosis development, but we believe that FAT10 may be a potential therapeutic target in treating patients with NASH-induced liver fibrosis. Here, UBD is linked to metabolic dysfunction-associated steatohepatitis.